Hay, Phillipa, and Bacaltchuk, Josué (2006) Bulimia Nervosa. Clinical Evidence, 15 . 1-23 .
|PDF (Published version) - Repository staff only - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader|
View at Publisher Website: http://clinicalevidence.bmj.com/ceweb/co...
INTRODUCTION: Up to 1% of young women may have bulimia nervosa, characterised by an intense preoccupation with body weight, uncontrolled binge-eating episodes, and use of extreme measures to counteract the feared effects of overeating. People with bulimia nervosa may be of normal weight, making it difficult to diagnose. After ten years, about half of people with bulimia nervosa will have recovered fully,a third will have made a partial recovery, and 10–20% will still have symptoms.
METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments for bulimia nervosa in adults? What are the effects of discontinuing treatment in people with bulimia nervosa in remission? We searched: Medline, Embase, The Cochrane Library and other important databases up to June 2007 (BMJ Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review).We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS:We found 26 systematic reviews, RCTs, or observational studies that met our inclusion criteria.We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: cognitive behavioural therapy (alone or plus exposure response prevention enhancement); cognitive orientation therapy; dialectical behavioural therapy; discontinuing fluoxetine in people with remission; guided self-help cognitive behavioural therapy; hypnobehavioural therapy; interpersonal psychotherapy; mirtazapine; monoamine oxidase inhibitors (MAOIs); motivational enhancement therapy; pharmacotherapy plus psychotherapy; pure or unguided self-help cognitive behavioural therapy (CBT); reboxetine; selective serotonin reuptake inhibitors (SSRIs); topiramate; tricyclic antidepressants (TCAs); and venlafaxine.
|Item Type:||Article (Refereed Research - C1)|
|Keywords:||Bulimia; antidepressant; cognitive / behavioral models|
|FoR Codes:||11 MEDICAL AND HEALTH SCIENCES > 1103 Clinical Sciences > 110399 Clinical Sciences not elsewhere classified @ 50%|
11 MEDICAL AND HEALTH SCIENCES > 1103 Clinical Sciences > 110319 Psychiatry (incl Psychotherapy) @ 50%
|SEO Codes:||92 HEALTH > 9205 Specific Population Health (excl. Indigenous Health) > 920507 Womens Health @ 51%|
92 HEALTH > 9204 Public Health (excl. Specific Population Health) > 920410 Mental Health @ 49%
|Deposited On:||24 Nov 2009 14:54|
|Last Modified:||28 Mar 2013 20:12|
Last 12 Months: 0
|Citation Counts with External Providers:|
Repository Staff Only: item control page